Hobusch Gerhard Martin, Bodner Florian, Walzer Sonja, Marculescu Rodrig, Funovics Philipp T, Sulzbacher Irene, Windhager Reinhard, Panotopoulos Joannis
Department of Orthopaedics, Medical University of Vienna, Waehringer Guertel 18 - 20, A-1090, Wien, Austria.
Department of Medical and Chemical Laboratory Diagnostics, Medical University of Vienna, Vienna, Austria.
World J Surg Oncol. 2016 Apr 18;14:111. doi: 10.1186/s12957-016-0875-8.
This is a retrospective, diagnostic study, level IV.
It appears to be necessary to identify prognostic markers for individual risk estimation for progression and survival in patients with chordoma, a rare disease. Are pre-operative serum levels of C-reactive protein (CRP) associated with disease progression and survival?
Survival rates of 24 patients (18 males, 6 females) (mean age 67 years (SD ± 16; range 20-85 years); minimum follow-up 2 years, mean follow-up 5 years (SD ± 5; range 2-19 years)) with chordoma of the lower spine and sacrum were assessed with a focus on pre-operative CRP levels.
The survival rate of patients with pre-operative CRP level of >1.0 mg/dl was lower than that of patients with a CRP level <1.0 mg/dl (p = 0.01). The estimated 10-year survival of patients with pre-operative CRP values <1.0 and >1.0 mg/dl was 76 and 25%, respectively. CRP remained as an independent survival factor (p = 0.025; CI 95% 1.0-2.6) in multivariable analysis.
Pre-operative CRP levels appear to be a biomarker for disease-specific survival in patients with chordoma of the lumbar spine and sacrum. A validation of our finding with larger cohorts and integration of putative risk factor would further elucidate CRP a surrogate for tumor progression.
这是一项回顾性诊断研究，为四级研究。
对于脊索瘤（一种罕见疾病）患者，似乎有必要确定用于个体进展和生存风险评估的预后标志物。术前血清C反应蛋白（CRP）水平是否与疾病进展和生存相关？
评估了24例下脊柱和骶骨脊索瘤患者（18例男性，6例女性）（平均年龄67岁（标准差±16；范围20 - 85岁）；最短随访2年，平均随访5年（标准差±5；范围2 - 19年））的生存率，重点关注术前CRP水平。
术前CRP水平>1.0 mg/dl的患者生存率低于CRP水平<1.0 mg/dl的患者（p = 0.01）。术前CRP值<1.0和>1.0 mg/dl的患者估计10年生存率分别为76%和25%。在多变量分析中，CRP仍然是一个独立的生存因素（p = 0.025；95%置信区间1.0 - 2.6）。
术前CRP水平似乎是腰椎和骶骨脊索瘤患者疾病特异性生存的生物标志物。通过更大队列验证我们的发现并整合假定的风险因素将进一步阐明CRP作为肿瘤进展的替代指标。
